(Q36390913)

13 August 2017

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy (English)

1 reference

13 August 2017

Donald A Hutcherson

1

1 reference

13 August 2017

David C Gammon

series ordinal

2

1 reference

13 August 2017

Mansi S Bhatt

series ordinal

3

1 reference

13 August 2017

Melissa Faneuf

series ordinal

4

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

13 August 2017

1 reference

13 August 2017

26

1 reference

13 August 2017

2

1 reference

13 August 2017

242-247

1 reference

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

13 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.242

Advances in the management of malignancy-associated hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.242

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.242

Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.242

Treatment of impending tumor lysis with single-dose rasburicase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.242

A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.2.242

21 January 2018

Identifiers

DOI

10.1592/PHCO.26.2.242

1 reference

13 August 2017

1 reference